We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Toni Choueiri MD

Toni K. Choueiri MD

Director, Lank Center for Genitourinary (GU) Oncology, Dana-Farber Cancer Institute/Brigham and Women’s Hospital; Jerome and Nancy Kohlberg Chair and Professor of Medicine, Harvard Medical School, Boston, Massachusetts

Recent Contributions to PracticeUpdate:

  1. Toni Choueiri on Clinically Impactful New RCC Data—PracticeUpdate's ESMO 2016 Coverage
  2. Cabozantinib Joins the RCC Lineup: Dr. Toni Choueiri on the METEOR Trial
  3. ECC Advice From Experts: Cabozantinib vs Everolimus in Patients With Advanced RCC
  4. Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients With RCC Receiving Sunitinib or Pazopanib

Most Read This Week

Recently Updated